UroGen Pharma Ltd.
URGN
$18.44
-$0.35-1.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 37.68% | 13.49% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 37.68% | 13.49% | |||
| Cost of Revenue | 0.34% | -7.66% | |||
| Gross Profit | 42.74% | 17.13% | |||
| SG&A Expenses | 4.70% | -13.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.80% | -16.44% | |||
| Operating Income | 30.20% | 33.93% | |||
| Income Before Tax | 22.56% | 29.69% | |||
| Income Tax Expenses | 73.91% | -203.84% | |||
| Earnings from Continuing Operations | 20.94% | 33.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.94% | 33.23% | |||
| EBIT | 30.20% | 33.93% | |||
| EBITDA | 27.90% | 36.17% | |||
| EPS Basic | 22.83% | 33.67% | |||
| Normalized Basic EPS | 24.41% | 30.15% | |||
| EPS Diluted | 22.83% | 33.67% | |||
| Normalized Diluted EPS | 24.41% | 30.15% | |||
| Average Basic Shares Outstanding | 2.44% | 0.67% | |||
| Average Diluted Shares Outstanding | 2.44% | 0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||